Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
removed 2,124,209 shares (-89.4%) from their portfolio in Q1 2026, for an estimated $1,940,273,742 STATE FARM MUTUAL AUTOMOBILE INSURANCE CO removed 1,721,029 shares (-13.8%) from their portfolio in Q1 2026, for an estimated $1,572,005,098 FIFTH THIRD BANCORP added 1,497,423 shares (+321.3%) to their portfolio in Q1 2026, for an estimated $1,367,761,142 ASSENAGON ASSET MANAGEMENT S.A
How does the PlexusDx Precision Peptide Genetic Test help me choose between semaglutide and tirzepatide
Researchers examine pulse-response behavior, metabolic signaling patterns, and peptide pathway comparisons under controlled experimental conditions
FDA's 2026 GLP-1 Warnings: 990 Reports and What They Mean for JoinSkinny Patients FDA has published ongoing warnings about compounded GLP-1 products generally: Dosing errors from measuring doses out of multi-dose vials Use of salt forms (like semaglutide sodium) that haven't been proven safe or effective Adverse events, including hospitalization in some cases As of May 31, 2026: 990 adverse-event reports tied to compounded semaglutide, and more than 730 tied to compounded tirzepatide - FDA notes these reports may be incomplete and don't, by themselves, establish that a compounded drug caused the reported event On April 30, 2026: FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list - a move that would close the main legal pathway for large-scale outsourcing-facility compounding of these drugs absent a shortage, with a public comment period that ran through June 29, 2026 These are industry-wide regulatory developments, not findings against JoinSkinny or any specific pharmacy named in this article
